08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

Bioventix, CardiNor deal

Bioventix will develop and provide antibodies for CardiNor’s Secretoneurin in vitro diagnostic (IVD) test. Secretoneurin is a neuropeptide shown to be an independent risk marker of cardiovascular disease. CardiNor plans to launch its test in...
07:00 , Aug 16, 2004 |  BC Week In Review  |  Company News

Bioventix Ltd., Roche deal

ROCZ's Roche Diagnostics GmbH subsidiary (Mannheim, Germany) received a non-exclusive license to use Bioventix's Sheep Monoclonal Antibody (SMA) technology for in-house clinical diagnostic research. Bioventix will receive a signing fee and annual license fees, and...
08:00 , Jan 19, 2004 |  BioCentury  |  Finance

Ebb & Flow

Investors look to the JPMorgan conference to kick off the year for life sciences, and last week's event in San Francisco did not disappoint. The nearly 5,500 "official" attendees made for packed halls and stuffed...
08:00 , Jan 12, 2004 |  BC Week In Review  |  Company News

Bioventix Ltd., Xenova deal

In line with its declared strategy, XEN sold to Bioventix certain assets obtained through its acquisition of KS Biomedix for £800,000 ($1.4 million) (see BioCentury, Aug. 18, 2003). The sale includes IP related to super...